Quarterly ResultMay 15, 2026, 07:47 AM
Immuneering Q1 Net Loss $13.5M; Pivotal Phase 3 Recruiting
AI Summary
Immuneering Corporation reported its first quarter 2026 financial results, ending the period with $198.6 million in cash, cash equivalents, and marketable securities, with an anticipated cash runway into 2029. The company posted a net loss of $13.5 million, or $0.21 per share. Operationally, Immuneering announced that its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line metastatic pancreatic cancer is now recruiting patients, with new survival data from its Phase 2a trial slated for presentation at the 2026 ASCO Annual Meeting.
Key Highlights
- Ended Q1 2026 with $198.6 million in cash, cash equivalents, and marketable securities.
- Reported a net loss of $13.5 million, or $0.21 per share, for Q1 2026.
- Research and Development (R&D) expenses decreased to $10.6 million in Q1 2026 from $11.5 million in Q1 2025.
- General and Administrative (G&A) expenses increased to $4.7 million in Q1 2026 from $4.0 million in Q1 2025.
- Pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line metastatic pancreatic cancer is now recruiting patients.
- New survival data from Phase 2a atebimetinib trial in pancreatic cancer to be presented at 2026 ASCO Annual Meeting on June 1, 2026.
- Anticipates cash runway to be sufficient to fund operations into 2029.
Price Impact
More from IMRX